| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Cyst | 29 | 2021 | 348 | 9.180 |
Why?
|
| Cytodiagnosis | 25 | 2022 | 420 | 6.420 |
Why?
|
| Pancreatic Neoplasms | 60 | 2021 | 5022 | 5.820 |
Why?
|
| Cyst Fluid | 12 | 2021 | 68 | 3.530 |
Why?
|
| Adenocarcinoma, Mucinous | 15 | 2021 | 483 | 3.400 |
Why?
|
| Pancreas | 20 | 2021 | 1693 | 2.990 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 10 | 2019 | 195 | 2.620 |
Why?
|
| Biopsy, Fine-Needle | 35 | 2022 | 1063 | 2.620 |
Why?
|
| Carcinoma, Pancreatic Ductal | 21 | 2020 | 1521 | 2.600 |
Why?
|
| Bile Duct Neoplasms | 9 | 2022 | 580 | 2.500 |
Why?
|
| Neuroendocrine Tumors | 8 | 2021 | 538 | 2.270 |
Why?
|
| Cystadenoma, Serous | 6 | 2021 | 101 | 1.920 |
Why?
|
| Pathology, Clinical | 7 | 2022 | 372 | 1.900 |
Why?
|
| Biliary Tract Neoplasms | 4 | 2019 | 176 | 1.720 |
Why?
|
| Carcinoembryonic Antigen | 11 | 2018 | 350 | 1.460 |
Why?
|
| Cholangiocarcinoma | 4 | 2022 | 526 | 1.300 |
Why?
|
| Bile Ducts | 6 | 2022 | 291 | 1.220 |
Why?
|
| Biopsy, Needle | 23 | 2019 | 1679 | 1.140 |
Why?
|
| Biliary Tract | 3 | 2015 | 140 | 1.000 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2020 | 791 | 0.980 |
Why?
|
| Preoperative Period | 5 | 2021 | 557 | 0.960 |
Why?
|
| Cystadenocarcinoma, Mucinous | 2 | 2013 | 49 | 0.940 |
Why?
|
| Societies, Medical | 9 | 2021 | 3776 | 0.930 |
Why?
|
| Endosonography | 12 | 2016 | 576 | 0.910 |
Why?
|
| Pancreatic Ducts | 6 | 2014 | 335 | 0.890 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2021 | 3698 | 0.870 |
Why?
|
| Terminology as Topic | 4 | 2020 | 1620 | 0.840 |
Why?
|
| Cystadenoma | 3 | 2018 | 84 | 0.810 |
Why?
|
| Duodenum | 3 | 2011 | 473 | 0.770 |
Why?
|
| Neoplastic Cells, Circulating | 5 | 2020 | 878 | 0.770 |
Why?
|
| Uterine Cervical Diseases | 1 | 2020 | 79 | 0.770 |
Why?
|
| Carcinoma, Papillary | 8 | 2016 | 797 | 0.760 |
Why?
|
| Cervix Uteri | 2 | 2020 | 577 | 0.760 |
Why?
|
| Triage | 2 | 2020 | 928 | 0.760 |
Why?
|
| Cystadenoma, Mucinous | 2 | 2016 | 57 | 0.710 |
Why?
|
| Diagnosis, Differential | 39 | 2020 | 13274 | 0.710 |
Why?
|
| Granular Cell Tumor | 1 | 2018 | 52 | 0.700 |
Why?
|
| Surgical Instruments | 2 | 2018 | 415 | 0.680 |
Why?
|
| Epithelial Cells | 5 | 2015 | 3694 | 0.650 |
Why?
|
| Sensitivity and Specificity | 24 | 2021 | 14903 | 0.650 |
Why?
|
| Antibodies | 3 | 2021 | 2442 | 0.630 |
Why?
|
| Liver Neoplasms | 7 | 2018 | 4101 | 0.630 |
Why?
|
| Practice Guidelines as Topic | 5 | 2016 | 7486 | 0.610 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2017 | 113 | 0.610 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2016 | 30 | 0.600 |
Why?
|
| Adenocarcinoma | 11 | 2020 | 6370 | 0.590 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 8 | 2017 | 1671 | 0.550 |
Why?
|
| Antibodies, Neoplasm | 2 | 2007 | 312 | 0.540 |
Why?
|
| Pathology, Surgical | 4 | 2022 | 149 | 0.500 |
Why?
|
| Histiocytosis, Sinus | 2 | 2010 | 49 | 0.480 |
Why?
|
| Immunohistochemistry | 16 | 2020 | 11777 | 0.480 |
Why?
|
| Gastric Mucosa | 2 | 2007 | 606 | 0.480 |
Why?
|
| Humans | 147 | 2022 | 717237 | 0.480 |
Why?
|
| Aged, 80 and over | 36 | 2020 | 58528 | 0.480 |
Why?
|
| Pancreatitis, Chronic | 3 | 2017 | 272 | 0.470 |
Why?
|
| Breast | 1 | 2021 | 1822 | 0.460 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2013 | 135 | 0.430 |
Why?
|
| Lymphangioma | 1 | 2011 | 66 | 0.430 |
Why?
|
| Dermatitis Herpetiformis | 1 | 2011 | 27 | 0.420 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2011 | 16 | 0.420 |
Why?
|
| Aged | 61 | 2020 | 162856 | 0.420 |
Why?
|
| Goiter, Nodular | 1 | 2010 | 23 | 0.410 |
Why?
|
| Middle Aged | 72 | 2022 | 215041 | 0.410 |
Why?
|
| Methemoglobinemia | 1 | 2011 | 46 | 0.410 |
Why?
|
| Dapsone | 1 | 2011 | 64 | 0.410 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 990 | 0.400 |
Why?
|
| Celiac Disease | 2 | 2011 | 753 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 4 | 2021 | 9597 | 0.390 |
Why?
|
| Tonsillar Neoplasms | 1 | 2010 | 54 | 0.380 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2004 | 2088 | 0.380 |
Why?
|
| Herpes Simplex | 1 | 2013 | 471 | 0.380 |
Why?
|
| Female | 87 | 2022 | 377909 | 0.370 |
Why?
|
| Adenoma | 4 | 2017 | 2118 | 0.370 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2020 | 1973 | 0.350 |
Why?
|
| Smad4 Protein | 3 | 2020 | 168 | 0.350 |
Why?
|
| Staining and Labeling | 3 | 2020 | 1157 | 0.330 |
Why?
|
| Genes, p16 | 2 | 2020 | 160 | 0.330 |
Why?
|
| Thyroid Nodule | 3 | 2009 | 738 | 0.330 |
Why?
|
| Herpesvirus 1, Human | 1 | 2013 | 728 | 0.320 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2020 | 848 | 0.320 |
Why?
|
| Male | 76 | 2021 | 351380 | 0.320 |
Why?
|
| Mucins | 2 | 2009 | 557 | 0.310 |
Why?
|
| ras Proteins | 1 | 2012 | 1117 | 0.300 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2022 | 288 | 0.280 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 39302 | 0.280 |
Why?
|
| Laboratories, Hospital | 3 | 2020 | 198 | 0.280 |
Why?
|
| Amylases | 2 | 2016 | 188 | 0.280 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2022 | 2661 | 0.280 |
Why?
|
| Chromogranins | 2 | 2016 | 174 | 0.280 |
Why?
|
| Adult | 51 | 2020 | 212451 | 0.270 |
Why?
|
| Neoplasm Invasiveness | 6 | 2015 | 3704 | 0.260 |
Why?
|
| Retrospective Studies | 24 | 2021 | 72614 | 0.250 |
Why?
|
| Thyroid Gland | 2 | 2008 | 1164 | 0.250 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 2 | 2016 | 217 | 0.250 |
Why?
|
| Amyloidosis | 2 | 2010 | 797 | 0.250 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2003 | 67 | 0.250 |
Why?
|
| Pathology | 3 | 2012 | 271 | 0.250 |
Why?
|
| Head and Neck Neoplasms | 4 | 2016 | 2745 | 0.250 |
Why?
|
| Constriction, Pathologic | 3 | 2022 | 1048 | 0.240 |
Why?
|
| Reference Standards | 3 | 2017 | 995 | 0.240 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 3323 | 0.240 |
Why?
|
| Adenoma, Pleomorphic | 2 | 1995 | 76 | 0.240 |
Why?
|
| Goblet Cells | 1 | 2005 | 268 | 0.230 |
Why?
|
| Sampling Studies | 3 | 2013 | 637 | 0.230 |
Why?
|
| Carcinoma, Acinar Cell | 3 | 2017 | 59 | 0.230 |
Why?
|
| Parotid Neoplasms | 2 | 1995 | 162 | 0.220 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2022 | 106 | 0.210 |
Why?
|
| Biopsy | 4 | 2020 | 6753 | 0.210 |
Why?
|
| Ampulla of Vater | 2 | 2017 | 142 | 0.210 |
Why?
|
| Image Cytometry | 1 | 2001 | 50 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2020 | 732 | 0.210 |
Why?
|
| Predictive Value of Tests | 10 | 2021 | 15271 | 0.210 |
Why?
|
| Needles | 2 | 2020 | 444 | 0.200 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 12607 | 0.200 |
Why?
|
| Neoplasms | 3 | 2022 | 20568 | 0.200 |
Why?
|
| Foam Cells | 1 | 2020 | 83 | 0.200 |
Why?
|
| Azo Compounds | 1 | 2020 | 122 | 0.190 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2020 | 54 | 0.190 |
Why?
|
| Vaginal Smears | 2 | 2002 | 500 | 0.190 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2021 | 160 | 0.190 |
Why?
|
| Preoperative Care | 4 | 2014 | 2365 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2020 | 2972 | 0.190 |
Why?
|
| Growth Disorders | 1 | 2005 | 648 | 0.190 |
Why?
|
| Ascitic Fluid | 1 | 2019 | 197 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 4697 | 0.180 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2020 | 73 | 0.180 |
Why?
|
| Thyroid Neoplasms | 6 | 2009 | 2229 | 0.180 |
Why?
|
| Therapeutic Irrigation | 1 | 2020 | 306 | 0.180 |
Why?
|
| Oxygen | 1 | 2011 | 4179 | 0.180 |
Why?
|
| Carcinoma | 4 | 2004 | 2325 | 0.180 |
Why?
|
| Prognosis | 12 | 2020 | 29226 | 0.180 |
Why?
|
| Mutation | 7 | 2020 | 29491 | 0.170 |
Why?
|
| Ultrasonography | 5 | 2008 | 5948 | 0.170 |
Why?
|
| Laboratories | 1 | 2022 | 442 | 0.170 |
Why?
|
| Pancreatectomy | 4 | 2021 | 855 | 0.170 |
Why?
|
| Cough | 2 | 2013 | 564 | 0.170 |
Why?
|
| Histological Techniques | 2 | 1997 | 211 | 0.170 |
Why?
|
| Reticulin | 1 | 1997 | 23 | 0.170 |
Why?
|
| Neoplasm Seeding | 2 | 2014 | 90 | 0.170 |
Why?
|
| Body Fluids | 1 | 2019 | 312 | 0.170 |
Why?
|
| DNA, Viral | 2 | 2016 | 2293 | 0.170 |
Why?
|
| Bronchoalveolar Lavage | 2 | 2020 | 118 | 0.170 |
Why?
|
| Coloring Agents | 1 | 2020 | 555 | 0.170 |
Why?
|
| Pericardial Effusion | 1 | 2019 | 234 | 0.160 |
Why?
|
| Genes, p53 | 1 | 2020 | 768 | 0.160 |
Why?
|
| Mass Screening | 1 | 2013 | 5213 | 0.160 |
Why?
|
| Macrophages, Alveolar | 1 | 2020 | 441 | 0.160 |
Why?
|
| Autoantibodies | 2 | 2005 | 2007 | 0.160 |
Why?
|
| Pancreatic Diseases | 2 | 2017 | 359 | 0.160 |
Why?
|
| Pleural Effusion | 1 | 2020 | 341 | 0.160 |
Why?
|
| Flow Cytometry | 3 | 2014 | 6132 | 0.160 |
Why?
|
| Skin | 1 | 2011 | 4355 | 0.160 |
Why?
|
| Communicable Disease Control | 2 | 2022 | 812 | 0.160 |
Why?
|
| Epidermal Cyst | 1 | 2017 | 66 | 0.150 |
Why?
|
| Hepatocytes | 1 | 2004 | 1249 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 3368 | 0.150 |
Why?
|
| Splenic Diseases | 1 | 2017 | 94 | 0.150 |
Why?
|
| Pelvis | 1 | 2020 | 698 | 0.150 |
Why?
|
| Interferometry | 2 | 2014 | 98 | 0.150 |
Why?
|
| Reproducibility of Results | 10 | 2019 | 19538 | 0.140 |
Why?
|
| Antibody Specificity | 2 | 2019 | 1173 | 0.140 |
Why?
|
| Adolescent | 16 | 2020 | 85139 | 0.140 |
Why?
|
| Sarcoma | 2 | 2019 | 1878 | 0.140 |
Why?
|
| Lung | 2 | 2022 | 9781 | 0.140 |
Why?
|
| Granuloma | 1 | 1998 | 331 | 0.140 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 1997 | 98 | 0.140 |
Why?
|
| False Negative Reactions | 3 | 2015 | 605 | 0.140 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 3061 | 0.140 |
Why?
|
| World Health Organization | 1 | 2021 | 1287 | 0.140 |
Why?
|
| Cell Nucleus | 5 | 2020 | 3018 | 0.140 |
Why?
|
| Lymphoma | 2 | 2001 | 1889 | 0.140 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 510 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 3016 | 0.130 |
Why?
|
| Heavy Chain Disease | 1 | 2014 | 28 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2014 | 20434 | 0.130 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2014 | 82 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 2000 | 525 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2013 | 3278 | 0.130 |
Why?
|
| Workload | 1 | 2020 | 859 | 0.130 |
Why?
|
| Lung Transplantation | 2 | 2020 | 1158 | 0.130 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2014 | 542 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2000 | 1666 | 0.130 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 284 | 0.130 |
Why?
|
| Cohort Studies | 7 | 2020 | 39887 | 0.130 |
Why?
|
| Human papillomavirus 16 | 1 | 2016 | 269 | 0.130 |
Why?
|
| Fasciitis | 1 | 2014 | 72 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 3968 | 0.130 |
Why?
|
| Research Report | 1 | 2017 | 359 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2022 | 2748 | 0.120 |
Why?
|
| Precancerous Conditions | 2 | 2015 | 944 | 0.120 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2014 | 1355 | 0.120 |
Why?
|
| Cecal Diseases | 2 | 2003 | 53 | 0.120 |
Why?
|
| Papillomavirus Infections | 2 | 2016 | 1515 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2016 | 4038 | 0.120 |
Why?
|
| Ovarian Neoplasms | 2 | 2004 | 4750 | 0.120 |
Why?
|
| Papilloma, Intraductal | 1 | 2012 | 21 | 0.110 |
Why?
|
| Mammary Glands, Animal | 1 | 2014 | 278 | 0.110 |
Why?
|
| Neoplasm Metastasis | 3 | 2004 | 5101 | 0.110 |
Why?
|
| Multimedia | 1 | 2012 | 72 | 0.110 |
Why?
|
| Diagnostic Errors | 3 | 2022 | 1274 | 0.110 |
Why?
|
| Calcinosis | 1 | 2020 | 1456 | 0.110 |
Why?
|
| Observer Variation | 2 | 2020 | 2681 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 869 | 0.110 |
Why?
|
| Neoplasm Staging | 7 | 2015 | 11200 | 0.110 |
Why?
|
| Prospective Studies | 7 | 2021 | 51275 | 0.110 |
Why?
|
| Carcinoma, Endometrioid | 1 | 1994 | 288 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2022 | 2268 | 0.100 |
Why?
|
| Ilium | 1 | 1992 | 158 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 2001 | 0.100 |
Why?
|
| Immunoglobulins | 1 | 2014 | 920 | 0.100 |
Why?
|
| Young Adult | 8 | 2020 | 56247 | 0.100 |
Why?
|
| Germinoma | 2 | 2004 | 138 | 0.100 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2009 | 681 | 0.100 |
Why?
|
| Group Processes | 1 | 2012 | 232 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 1535 | 0.100 |
Why?
|
| Oropharynx | 1 | 2010 | 131 | 0.090 |
Why?
|
| Algorithms | 6 | 2014 | 13718 | 0.090 |
Why?
|
| Pancreatitis | 2 | 2007 | 1064 | 0.090 |
Why?
|
| Telepathology | 1 | 2009 | 75 | 0.090 |
Why?
|
| Watchful Waiting | 1 | 2013 | 457 | 0.090 |
Why?
|
| Liver Diseases | 1 | 1997 | 1254 | 0.090 |
Why?
|
| Hemolysis | 1 | 2011 | 412 | 0.090 |
Why?
|
| Carcinoma in Situ | 2 | 2013 | 820 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1669 | 0.090 |
Why?
|
| Chromatin | 1 | 2020 | 2741 | 0.090 |
Why?
|
| Tomography, Optical Coherence | 2 | 2014 | 2493 | 0.090 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1779 | 0.090 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 1991 | 263 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2010 | 757 | 0.090 |
Why?
|
| Palpation | 1 | 2008 | 172 | 0.080 |
Why?
|
| Radiography | 2 | 2013 | 7001 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2014 | 629 | 0.080 |
Why?
|
| Oximetry | 1 | 2011 | 468 | 0.080 |
Why?
|
| Communication | 2 | 2022 | 3516 | 0.080 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2015 | 490 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 6294 | 0.080 |
Why?
|
| Patient Participation | 1 | 2017 | 1477 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2013 | 2973 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2013 | 1916 | 0.080 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2007 | 110 | 0.080 |
Why?
|
| Papillomaviridae | 1 | 2013 | 1144 | 0.080 |
Why?
|
| Accreditation | 1 | 2010 | 449 | 0.080 |
Why?
|
| Calcium | 1 | 2020 | 5832 | 0.080 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2006 | 133 | 0.080 |
Why?
|
| Remote Consultation | 1 | 2009 | 251 | 0.080 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 683 | 0.080 |
Why?
|
| Breast Neoplasms | 4 | 2016 | 20083 | 0.080 |
Why?
|
| Oxyphil Cells | 1 | 2006 | 45 | 0.070 |
Why?
|
| Genes, ras | 1 | 2009 | 720 | 0.070 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2012 | 998 | 0.070 |
Why?
|
| Cytological Techniques | 2 | 2020 | 219 | 0.070 |
Why?
|
| Cystectomy | 1 | 2010 | 632 | 0.070 |
Why?
|
| Bronchogenic Cyst | 1 | 2005 | 29 | 0.070 |
Why?
|
| Gastric Fundus | 1 | 2005 | 37 | 0.070 |
Why?
|
| Prednisone | 1 | 2010 | 1548 | 0.070 |
Why?
|
| Melanosomes | 2 | 2002 | 34 | 0.070 |
Why?
|
| Intussusception | 1 | 2006 | 121 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2014 | 34502 | 0.070 |
Why?
|
| Endometrial Neoplasms | 1 | 1994 | 1343 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 3956 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2013 | 1144 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 3778 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 805 | 0.070 |
Why?
|
| Lymph Nodes | 2 | 2010 | 3433 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2003 | 996 | 0.070 |
Why?
|
| Choriocarcinoma | 1 | 2004 | 127 | 0.060 |
Why?
|
| Adrenal Medulla | 1 | 2003 | 59 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2010 | 769 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 13612 | 0.060 |
Why?
|
| Puberty, Delayed | 1 | 2005 | 114 | 0.060 |
Why?
|
| S100 Proteins | 2 | 2002 | 262 | 0.060 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2009 | 628 | 0.060 |
Why?
|
| Stomach Diseases | 1 | 2005 | 130 | 0.060 |
Why?
|
| Teaching | 1 | 2012 | 1189 | 0.060 |
Why?
|
| Transglutaminases | 1 | 2005 | 187 | 0.060 |
Why?
|
| False Positive Reactions | 2 | 2009 | 999 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2010 | 2100 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 1845 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 1160 | 0.060 |
Why?
|
| Point Mutation | 1 | 2009 | 1658 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 2572 | 0.060 |
Why?
|
| Consensus | 1 | 2012 | 2755 | 0.060 |
Why?
|
| alpha-Fetoproteins | 1 | 2004 | 220 | 0.060 |
Why?
|
| Melanoma | 1 | 2001 | 5260 | 0.060 |
Why?
|
| Keratins | 2 | 2004 | 531 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 1486 | 0.060 |
Why?
|
| Appendix | 1 | 2003 | 113 | 0.060 |
Why?
|
| Ileal Diseases | 1 | 2002 | 70 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2010 | 2510 | 0.060 |
Why?
|
| Lumbar Vertebrae | 1 | 1992 | 1842 | 0.060 |
Why?
|
| Cell Separation | 2 | 2020 | 1829 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 4636 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4259 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1997 | 2968 | 0.060 |
Why?
|
| Appendiceal Neoplasms | 1 | 2003 | 118 | 0.050 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2002 | 69 | 0.050 |
Why?
|
| Gallbladder Neoplasms | 1 | 2003 | 161 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2017 | 21805 | 0.050 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2001 | 63 | 0.050 |
Why?
|
| Kidney Neoplasms | 2 | 1998 | 4046 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 2003 | 338 | 0.050 |
Why?
|
| Genomics | 1 | 2017 | 5338 | 0.050 |
Why?
|
| Pattern Recognition, Automated | 1 | 2008 | 1017 | 0.050 |
Why?
|
| Radiographic Image Enhancement | 1 | 2006 | 921 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2005 | 695 | 0.050 |
Why?
|
| Vimentin | 1 | 2001 | 276 | 0.050 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2001 | 127 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2011 | 2334 | 0.050 |
Why?
|
| Risk Assessment | 5 | 2019 | 23542 | 0.050 |
Why?
|
| Epithelioid Cells | 1 | 2020 | 74 | 0.050 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 1999 | 21 | 0.050 |
Why?
|
| Risk | 1 | 2012 | 9773 | 0.050 |
Why?
|
| STAT6 Transcription Factor | 1 | 2020 | 208 | 0.050 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2001 | 194 | 0.050 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 1999 | 39 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 9000 | 0.050 |
Why?
|
| Necrosis | 1 | 2003 | 1650 | 0.050 |
Why?
|
| Exudates and Transudates | 1 | 2019 | 181 | 0.050 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2008 | 1028 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2003 | 463 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 1992 | 2594 | 0.040 |
Why?
|
| Cardiomyopathies | 1 | 2010 | 1831 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 1407 | 0.040 |
Why?
|
| Medical Records | 1 | 2004 | 1421 | 0.040 |
Why?
|
| Diagnostic Imaging | 2 | 2012 | 3496 | 0.040 |
Why?
|
| Eyelid Neoplasms | 1 | 1999 | 88 | 0.040 |
Why?
|
| Testicular Neoplasms | 1 | 2004 | 769 | 0.040 |
Why?
|
| Image Enhancement | 2 | 2008 | 2979 | 0.040 |
Why?
|
| Salivary Ducts | 1 | 1997 | 24 | 0.040 |
Why?
|
| Education, Medical | 1 | 2010 | 1691 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2000 | 365 | 0.040 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2003 | 736 | 0.040 |
Why?
|
| Endoscopy | 1 | 2008 | 1758 | 0.040 |
Why?
|
| Body Height | 1 | 2005 | 1589 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2003 | 1362 | 0.040 |
Why?
|
| Cysts | 1 | 2002 | 638 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2021 | 518 | 0.040 |
Why?
|
| Chondrosarcoma | 1 | 2000 | 313 | 0.040 |
Why?
|
| Reference Values | 1 | 2005 | 5058 | 0.040 |
Why?
|
| Urine | 1 | 1998 | 380 | 0.040 |
Why?
|
| Fungi | 1 | 2020 | 329 | 0.040 |
Why?
|
| Anesthesia | 1 | 2008 | 1515 | 0.040 |
Why?
|
| Intestines | 1 | 2006 | 1932 | 0.040 |
Why?
|
| Fixatives | 1 | 2016 | 102 | 0.040 |
Why?
|
| Cell Count | 1 | 2020 | 1920 | 0.040 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2016 | 135 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 6778 | 0.040 |
Why?
|
| Automation, Laboratory | 1 | 2016 | 98 | 0.040 |
Why?
|
| Adenoma, Bile Duct | 1 | 1995 | 30 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 1262 | 0.040 |
Why?
|
| Guidelines as Topic | 2 | 2014 | 1418 | 0.030 |
Why?
|
| Canada | 1 | 2020 | 1956 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 1741 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2020 | 652 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2016 | 257 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 319 | 0.030 |
Why?
|
| ROC Curve | 2 | 2014 | 3532 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2016 | 366 | 0.030 |
Why?
|
| Filtration | 1 | 2015 | 238 | 0.030 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1999 | 522 | 0.030 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2016 | 387 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 3421 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 1208 | 0.030 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1997 | 296 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2006 | 1639 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 1995 | 299 | 0.030 |
Why?
|
| Body Weight | 1 | 2005 | 4691 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2005 | 2113 | 0.030 |
Why?
|
| Ethanol | 1 | 2000 | 1260 | 0.030 |
Why?
|
| Vagina | 1 | 1998 | 779 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2014 | 758 | 0.030 |
Why?
|
| Hysterectomy | 1 | 1998 | 908 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2019 | 10542 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2016 | 1988 | 0.030 |
Why?
|
| Adipose Tissue | 2 | 2014 | 3243 | 0.030 |
Why?
|
| Massachusetts | 1 | 2004 | 8749 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 1594 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 956 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2020 | 2425 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 718 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2009 | 11758 | 0.020 |
Why?
|
| Child | 4 | 2020 | 74387 | 0.020 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 1992 | 235 | 0.020 |
Why?
|
| Basement Membrane | 1 | 1991 | 359 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1998 | 1441 | 0.020 |
Why?
|
| Survival Rate | 2 | 2015 | 13261 | 0.020 |
Why?
|
| Infant | 3 | 2020 | 34574 | 0.020 |
Why?
|
| Muscles | 1 | 2014 | 1630 | 0.020 |
Why?
|
| Bacteria | 1 | 2020 | 2098 | 0.020 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1998 | 1308 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2012 | 342 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2020 | 41221 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 1841 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2014 | 2845 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2018 | 4921 | 0.020 |
Why?
|
| Geography | 1 | 2010 | 690 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 13754 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 4312 | 0.020 |
Why?
|
| Curriculum | 2 | 2010 | 3403 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 1490 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 2935 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2014 | 1566 | 0.020 |
Why?
|
| Colloids | 1 | 2006 | 145 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2011 | 651 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2010 | 516 | 0.020 |
Why?
|
| Macrophages | 1 | 2020 | 5814 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5438 | 0.020 |
Why?
|
| Metaplasia | 1 | 2006 | 310 | 0.020 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2004 | 47 | 0.020 |
Why?
|
| United States | 3 | 2020 | 67798 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2010 | 721 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 3089 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 1563 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 4916 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 13317 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2014 | 4286 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2020 | 62348 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 2536 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 2004 | 461 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2015 | 8066 | 0.010 |
Why?
|
| Lymphatic Metastasis | 2 | 2002 | 2975 | 0.010 |
Why?
|
| Liver | 1 | 1998 | 7628 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2010 | 1282 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 1762 | 0.010 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2002 | 84 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 11336 | 0.010 |
Why?
|
| Gallbladder Diseases | 1 | 2003 | 127 | 0.010 |
Why?
|
| Publishing | 1 | 2009 | 800 | 0.010 |
Why?
|
| Pandemics | 1 | 2022 | 7292 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 3564 | 0.010 |
Why?
|
| Cell Nucleolus | 1 | 2002 | 176 | 0.010 |
Why?
|
| Testis | 1 | 2004 | 809 | 0.010 |
Why?
|
| Diverticulitis | 1 | 2003 | 169 | 0.010 |
Why?
|
| Cholecystectomy | 1 | 2003 | 394 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 1173 | 0.010 |
Why?
|
| Disease Progression | 1 | 2017 | 13307 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2012 | 2595 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 16017 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2003 | 796 | 0.010 |
Why?
|
| Boston | 1 | 2011 | 9407 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 4993 | 0.010 |
Why?
|
| Patient Selection | 1 | 2010 | 4321 | 0.010 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 2210 | 0.010 |
Why?
|
| Endodermal Sinus Tumor | 1 | 1997 | 53 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 16989 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 12483 | 0.010 |
Why?
|
| Seminoma | 1 | 1997 | 118 | 0.010 |
Why?
|
| Mice | 2 | 2014 | 81126 | 0.010 |
Why?
|
| Radiology, Interventional | 1 | 2000 | 423 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12417 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 1741 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2002 | 753 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 2707 | 0.010 |
Why?
|
| Endometriosis | 1 | 2003 | 803 | 0.010 |
Why?
|
| Teratoma | 1 | 1997 | 390 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 2004 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2005 | 1996 | 0.010 |
Why?
|
| Animals | 2 | 2014 | 170890 | 0.010 |
Why?
|
| Colitis, Ulcerative | 1 | 2003 | 1814 | 0.010 |
Why?
|
| Logistic Models | 1 | 2006 | 13601 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 9047 | 0.010 |
Why?
|
| Crohn Disease | 1 | 2003 | 2255 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 70864 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 11008 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 2532 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 1998 | 10651 | 0.000 |
Why?
|